Provided by Tiger Trade Technology Pte. Ltd.

MoonLake Immunotherapeutics

15.31
-0.4500-2.86%
Volume:340.20K
Turnover:5.24M
Market Cap:1.30B
PE:-4.01
High:15.68
Open:15.68
Low:15.25
Close:15.76
52wk High:62.75
52wk Low:5.95
Shares:85.11M
Float Shares:55.47M
Volume Ratio:0.79
T/O Rate:0.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8139
EPS(LYR):-3.5300
ROE:-67.47%
ROA:-32.44%
PB:3.04
PE(LYR):-4.34

Loading ...

Moonlake Immunotherapeutics CSO Kristian Reich Sells 43,700 Shares for $877,933

Reuters
·
Jul 22

Moonlake Immunotherap Price Target Maintained with a $45.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 20

Moonlake Immunotherapeutics CSO Kristian Reich Sells 16,105 Shares for $322,261.05

Reuters
·
Jul 20

Moonlake CEO Jorge Santos Da Silva Sells $2.05 Million of Common Shares

Reuters
·
Jul 14

Moonlake CEO Jorge Santos Da Silva Sells 47,775 Shares for $956,918.25

Reuters
·
Jul 03

Moonlake Immunotherap is Maintained at Outperform by Leerink Partners

Dow Jones
·
Jul 01

MoonLake Immunotherapeutics Announces $200 Million Public Offering

TIPRANKS
·
Jun 25

Moonlake Immunotherapeutics Slides After $200 Mln Share Sale

Reuters
·
Jun 24

H.C. Wainwright Remains a Buy on MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
Jun 24

BRIEF-Moonlake Prices Offering Of 9 Million Class A Shares At $20/Share

Reuters
·
Jun 24

MoonLake Immunotherapeutics prices upsized public offering at USD 200 million

Reuters
·
Jun 24

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering

THOMSON REUTERS
·
Jun 24

MoonLake: Prices Offering of 9 Mln Class a Shares at $20 per Share

THOMSON REUTERS
·
Jun 24

MoonLake CFO Matthias Bodenstedt sells 39,120 shares for $862,205.60

Reuters
·
Jun 24

MoonLake Immunotherapeutics announces $150M offering of Class A ordinary shares

TIPRANKS
·
Jun 23

MoonLake Immunotherapeutics Shares Fall About 4% to $21.28 After the Bell Following Public Offering Announcement

THOMSON REUTERS
·
Jun 23

MoonLake Immunotherapeutics plans USD 150 million follow-on share offering

Reuters
·
Jun 23

MoonLake Immunotherapeutics - Announces Proposed $150 Mln Public Offering of Class a Shares and Pre-Funded Warrants

THOMSON REUTERS
·
Jun 23

MoonLake Immunotherapeutics - Proceeds to Fund Sonelokimab Activities and General Corporate Purposes

THOMSON REUTERS
·
Jun 23

MoonLake’s SLK has ‘blockbuster potential,’ says Clear Street

TIPRANKS
·
Jun 23